Protocols for Laboratory Verification of Performance of the FilmArray Respiratory Panel 2 plus (RP2plus)

Similar documents
Protocols for Laboratory Verification of Performance of the FilmArray Respiratory Panel (RP)

Protocols for Laboratory Verification of Performance of the FilmArray Respiratory Panel (RP) EZ

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel

Protocols for Laboratory Verification of Performance of the BioFire FilmArray Pneumonia Panel plus

Lab Alert REMINDER: BioFire- FilmArray Respiratory Panel

PATHOGEN DETECTION WITH THE FILMARRAY

Proficiency Testing Materials for use with FilmArray Panels

PAMET Continuing Education 2016

Potential Reimbursement CPT Codes

Proficiency Testing Materials for use with BioFire FilmArray Panels

AMPLIRUN TOTAL A RELIABLE QUALITY CONTROL SOURCE FOR NUCLEIC ACID TESTS

Respiratory Pathogen Panel TEM-PCR Test Code:

FilmArray Respiratory Panel Quick Guide

MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels

Screening (and Diagnosis) of 15 Respiratory Viruses Using NAAT

Coordinate shipping to the Oregon State Public Health Lab through your local health department

Human Influenza A (Swine Flu) Rapid test

Retrospective and Prospective Verification of the Cepheid Xpert Flu Assay

October Influenza Testing for the Season. Lauren Anthony, MD, MT(ASCP)SBB Medical Director, Allina Medical Laboratories

Test Menu. Infectious Diseases Laboratory. Division of Infectious Diseases Department of Medicine

MENU PRODUCT MOLECULAR. International Product Listing. Simplexa Molecular Kits Integrated Cycler Molecular Reagents and Primer Pairs

COLLECTION GUIDELINE FOR LABORATORY DIAGNOSIS OF COMMON VIRAL INFECTIONS

Rapid-VIDITEST. Influenza A+B

INFINITI FLU A-sH1N1 Assay Directional Package Insert (DPI)

Syndromic Testing: The right test, the first time.

Rapid-VIDITEST Swine Flu

Comparison of the eplex Respiratory Pathogen Panel with Laboratory Developed Real-

MolDX: Multiplex Nucleic Acid Amplified Tests for Respiratory Viral Panels

RESPIRATORY WATCH Week 3 (January 14 to January 20, 2018)*

RESPIRATORY WATCH Week 2 (January 6, 2019 to January 12, 2019 )*

MICROBIOLOGICAL TESTING IN PICU

INFECTIOUS DISEASE. Page 2

Rapid-VIDITEST. Influenza A

Alkaline Phosphatase, Bone Specific

Molecular Diagnostics at Point of Care It s The Future Already. Ack!

Respiratory Multiplex Array. Rapid, simultaneous detection of 22 bacterial and viral pathogens of the upper and lower respiratory tract

Evaluation of the BioFire FilmArray Respiratory Panel and the GenMark esensor Respiratory Viral Panel on Lower Respiratory Tract Specimens

DiagCORE Respiratory Panel 2. Instructions for use PL /2018-EN

Respiratory virus associated communityacquired pneumonia in Western Australian Children: case-control study

Influenza Weekly Surveillance Bulletin

Comparison of Luminex NxTAG Respiratory Pathogen Panel and xtag Respiratory Viral Panel FAST Version 2 for the Detection of Respiratory Viruses

Likelihood that an unsubtypeable Influenza A result. in the Luminex xtag Respiratory Virus Panel. is indicative of novel A/H1N1 (swine-like) influenza

Line Listing and Specimen Collection. Module 5

MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 4, 2019

FOR IN VITRO DIAGNOSTIC USE

Influenza A & B Screening

Comparison of Two Multiplex Methods for Detection of Respiratory Viruses: FilmArray RP and xtag RVP

Creating a User Defined Pneumonia-Specific Syndrome in ESSENCE. Preventive Medicine Directorate September 2016

POC TESTING: COST V CONVENIENCE. Presented by: Jim Poggi Principal Tested Insights, LLC January 29, 2019

CONTAGIOUS COMMENTS Department of Epidemiology

an inflammation of the bronchial tubes

MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH WEEKLY INFLUENZA UPDATE January 26, 2018

RESPIRATORY VIRUS SURVEILLANCE REPORT

CONTAGIOUS COMMENTS Department of Epidemiology

USER GUIDE FOR SPECIMEN COLLECTION

2017/18 Influenza Season Summary

ARIZONA INFLUENZA SUMMARY Week 1 (1/4/2015 1/10/2015)

SISEA Surveillance and Investigation of Epidemic Situations in South-East Asiaww

Table 1: Summary of Texas Influenza (Flu) and Influenza-like Illness (ILI) Activity for the Current Week Texas Surveillance Component

Received 4 December 2006/Returned for modification 4 April 2007/Accepted 17 June 2007

QUICK REFERENCE INSTRUCTIONS For use with Sofia only.

RealLine Mycoplasma genitalium Str-Format

Product # Kit Components

Influenza Weekly Surveillance Bulletin

QUALITY CONTROL for MOLECULAR DIAGNOSTICS Quality issues highlighted through international external quality assessment

Redefine Performance. BD Veritor. System Revolutionizes Testing at the Point of Care. Fast. Streamlined Workflow Requires minimal hands-on time

altona RealStar Instructions for Use RealStar Influenza Screen & Type RT-PCR Kit /2017 EN DIAGNOSTICS

1. Intended Use New Influenza A virus real time RT-PCR Panel is used for the detection of universal influenza A virus, universal swine Influenza A vir

TEST REQUEST INFORMATION- VIROLOGY

Rapid Detection FAQs

M. Khanna and S. Visuri

Technical Bulletin No. 98b

4. RED AND BLUE TOP COLLECTION SWABS WILL NO LONGER BE SUPPLIED FOR BACTERIAL CULTURE

S. Wesley Long, MD, PhD

Influenza Weekly Surveillance Bulletin

Influenza Surveillance in Ireland Weekly Report Influenza Week (12 th 18 th November 2018)

MICROBIOLOGY SPECIMEN COLLECTION MANUAL

Molecular Diagnostics at Point of Care When will we get there; and where is there anyway?

At the forefront of multiplex PCR

Summary: High Activity

Simplexa Flu A/B & RSV Direct

and Bacterial Respiratory Tract Pathogens in Nasopharyngeal Swabs

Norgen s HIV proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad icycler

Norgen s HIV Proviral DNA PCR Kit was developed and validated to be used with the following PCR instruments: Qiagen Rotor-Gene Q BioRad T1000 Cycler

In the name of God. Respiratory Viruses. An Overview

New viruses causing respiratory tract infections. Eric C.J. Claas

From the Department of Laboratory Medicine and Pathology, University of Minnesota Medical School, Minneapolis.

Summary: Increasing Activity

QUICK REFERENCE INSTRUCTIONS

Surveillance of Influenza In Northern Ireland

M O L E C U L A R G E N E T I C S

Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children

Validation FTD Respiratory pathogens 33

High Activity. Since Sept. 1, 2018: Hospitalizations: 62 ICU* admissions: 8 Deaths: <5. Syndromic in Community Syndromic in Care Syndromic in ED

Pneumonia Aetiology Why is it so difficult to distinguish pathogens from innocent bystanders?

Surveillance of influenza in Northern Ireland

No Laboratory-confirmed Influenza Activity

Influenza Laboratory Surveillance DSHS Flu Surveillance Workshop Lesley Brannan, MPH

Decreasing Activity. Since Sept. 1, 2018: Hospitalizations: 93 ICU* admissions: 16 Deaths: 5. Syndromic in Community Syndromic in Care Syndromic in ED

Transcription:

Protocols for Laboratory Verification of Performance of the FilmArray Respiratory Panel 2 plus (RP2plus) Purpose The Clinical Laboratory Improvement Amendments (CLIA), passed in 1988, establishes quality standards for all laboratory testing to ensure the accuracy and reliability of patient test results, regardless of where the test is performed. The CLIA regulations include a requirement for verifying the performance specifications of unmodified, moderate complexity tests cleared or approved by the FDA. This document provides examples of procedures to assist your laboratory in developing a protocol for the verification of FilmArray RP2plus performance on FilmArray 2.0 and Torch Systems as required by CLIA. Two possible verification schemes, compatible with the FilmArray RP2plus, have been designed. Each verification scheme provides positive and negative tests for each organism detected by the FilmArray RP2plus and may be easily modified or expanded to meet specific criteria. Day-to-day variation is evaluated by testing each sample on two separate days. To evaluate user-to-user variation, multiple laboratory technicians may test the same sample. In addition, testing patient samples for verification or to evaluate matrix effects on the performance of the FilmArray RP2plus should be done under the guidance of the Laboratory Director, but is not described here. As per the CLIA regulation, the Laboratory Director is ultimately responsible for ensuring that verification procedures meet the appropriate standards for CLIA and applicable laboratory accrediting agencies. FilmArray Intended Use FilmArray RP2plus is a multiplexed nucleic acid test intended for use with FilmArray 2.0 and Torch Systems for the simultaneous qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections in cases where MERS-CoV may be epidemiologically relevant. The following organisms and subtypes are identified using the FilmArray RP2plus: adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, enterovirus, human metapneumovirus, influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype 2009 H1, influenza B, Middle East Respiratory Syndrome Coronavirus, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus, respiratory syncytial virus, Bordetella parapertussis, B. pertussis, Chlamydia pneumoniae, and Mycoplasma pneumoniae. The complete intended use statement and additional information about the use of the FilmArray System can be found in the FilmArray Respiratory Panel 2 plus Instruction Booklet. 1 P a g e FLM1-PRT-0240-01

Performance Verification: Overview Each procedure described below will generate multiple positive and negative results for each of the FilmArray Respiratory Panel 2 plus (RP2plus) assays. The procedures were developed using a Respiratory Verification Panel available from ZeptoMetrix Corporation, Buffalo, NY (part number NATRVP2-BIO and NATCOV(MR)-BIO). Two different examples of performance verification procedures are described: (1) a Simple Protocol for the verification of FilmArray RP2plus performance and (2) a Viral Transport Media (VTM) Protocol that evaluates FilmArray RP2plus performance when organisms are in a VTM sample matrix. These protocols are examples of procedures to assist your laboratory in developing a protocol for the verification of FilmArray RP2plus performance on FilmArray 2.0 and Torch Systems. A FilmArray System is defined as one or more FilmArray Instruments or modules connected to and controlled by a single computer system. If the laboratory director chooses not to perform the verification protocol on each individual instrument, it is advised that test replicates are evenly distributed among the instruments. Performance verification protocols should be designed to take advantage of the multiplex nature of the FilmArray RP2plus. Verification testing efficiency is maximized by evaluating multiple target organisms in a single test run. In addition to, or in place of, the verification protocol examples described here, a laboratory may choose to test clinical/patient samples to assess clinical sensitivity and sample matrix effects in its performance verification of the FilmArray RP2plus. Table 1. Overview of Verification Protocols Number Organisms of per Pool a Sample Pools Verification Protocol Example 1: Simple protocol Example 2: Viral Transport Medium (VTM) protocol Replicates per Sample Pool Pouches Required 5 or 6 4 4 16 5 or 6 4 4 16 Expected Postive Results 4 per organism 4 per organism a Depending on the material used for verification, pooling of organisms may not be appropriate and the values in the table may need to be modified. b The approximate number of days for testing assumes a system configured with one instrument. Expected Negative Results 12 per organism 12 per organism Approximate Days of Testing b 4 4 2 P a g e FLM1-PRT-0240-01

Performance Verification: Materials The following materials may be needed to perform verification procedures: Table 2. Materials needed for recommended verification protocols Material FilmArray Respiratory Panel 2 plus (RP2plus) Kit (30 tests) FilmArray Respiratory Panel 2 plus (RP2plus) Instruction for Use FilmArray Respiratory Panel 2 plus (RP2plus) Quick Guide Control Organism Part Number (RFIT-ASY-0136) (RFIT-PRT-0818) (RFIT-PRT-0778) ZeptoMetrix NATRVP2-BIO + NATCOV(MR)-BIO Transport Medium (e.g. Remel M4 Viral Transport Media) 5mL sample tubes Transfer pipettes Various media are appropriate VWR Part # 89497-740 (or similar) VWR Part # 13-711-43 (or similar) a Any appropriate source of organism may be used for verification of any or all of the assays in the FilmArray RP2. However, when alternate organism sources are used (i.e. not the ZeptoMetrix TBD material), the sample volumes or pooling schemes suggested in the examples below may need to be adjusted. Performance Verification: Protocols Simple Protocol The Simple Protocol utilizes samples prepared by pooling together either 5 or 6 different organisms (ZeptoMetrix NATRVP2-BIO and NATCOV(MR)-BIO). The proposed organism pooling scheme (Table 3) should be followed to obtain the expected number of positive and negative results for each assay in a time and resource-efficient manner. Note: Dilution of ZeptoMetrix Respiratory Verification Panel organisms beyond levels proposed in these guidelines may lead to inconsistent results and is not recommended. The Simple Protocol can be followed to test a total of 16 pooled samples, providing 4 positive results and 12 negative results per assay. The number of samples tested per day should be determined by the individual laboratory. The testing scheme can be modified to run more samples per day based on the number of instruments configured on the FilmArray System. Pooled samples can be stored overnight (or up to 3 days) at refrigeration temperature (2 8 C) for subsequent testing to evaluate day-to-day variation. 3 P a g e FLM1-PRT-0240-01

Table 3. Proposed Organism Pooling Scheme Pool 1 Organism Adenovirus Type 3 Influenza A 2009 H1N1 Approximate organism volume Approximate Final Volume of Pool Influenza B 1.5 ml Parainfluenza virus Type 4 Coronavirus OC43 Pool 2 Rhinovirus 1 A Influenza A subtype H3 Coronavirus 229E Parainfluenza virus Type 1 1.8 ml Parainfluenza virus Type 2 Middle East Respiratory Syndrome (MERS-CoV) Pool 3 Adenovirus Type 1 Influenza A H1N1 Parainfluenza virus Type 3 Respiratory Syncytial Virus A 1.8 ml Coronavirus NL63 Bordetella parapertussis Pool 4 Adenovirus Type 31 Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae 1.8 ml Coronavirus HKU1 Human Metapneumovirus 8 An example Simple Protocol workflow is provided below. Simple Protocol Example The estimated total time for completion for this Simple Protocol verification example is 4 days for a FilmArray 2.0 or Torch System configured with 1 module. A proposed organism pooling scheme is presented above in Table 3. Note: Extreme care should be taken to avoid contamination of the lab environment, especially work surfaces, with control material. Clean work surfaces frequently and change gloves often. MERS-CoV contamination presents a particular risk for false positives due to its low prevalence in the population. 4 P a g e FLM1-PRT-0240-01

Day 1 1. Prepare two sample pools (i.e. pools #1 and #2, in Table 3 above) from ZeptoMetrix NATRVP2-BIO control material. Note: It is important to prepare only the number of sample pools that will be tested within 3 days of preparation. The suggestion to prepare 2 sample pools is based on testing 4 pouches per day. The number of samples prepared may be increased or decreased based on the laboratory s work schedule and number of instruments connected within a FilmArray System. a. Use a transfer pipette to remove material from the ZeptoMetrix organism vial (draw material to the third line of the transfer pipette) and transfer to a new vial or tube. b. Repeat with the second (and subsequent) organisms to combine the appropriate organisms into a single vial or tube (approximately 1.5 ml total volume for five organisms or 1.8 ml for six organisms). c. Cap and vortex prior to testing. 2. Test two samples from a single sample pool. The duplicate samples should be tested in a single day by different users. Note: For each sample, follow instructions in the FilmArray Respiratory Panel 2 plus Instruction Booklet and FilmArray Respiratory Panel 2 plus Quick Guide for pouch preparation, pouch hydration, sample loading, and sample testing. 3. Repeat Step 2 for the remaining sample pools (i.e. pool #2) to be tested that day. 4. Refrigerate samples (2 8 C) for up to 3 days for the evaluation of day-to-day variation. Day 2 To evaluate day-to-day variation, test the remaining volume of the sample pools prepared on Day 1 by repeating Step 2 and 3 above. Day 3 Prepare 2 new sample pools (i.e. pools #3 and #4) as described in Step 1. Test samples according to Step 2 and 3 above. Day 4 To evaluate day-to-day variation, test the samples prepared on Day 3 by repeating Step 2 and 3 above. Note: The remaining material from Zeptometrix NATRVP2-BIO may be stored according to manufacturer s instructions for use at a later date. 5 P a g e FLM1-PRT-0240-01

Figure 1. Workflow for Simple Protocol VTM Protocol The VTM Protocol evaluates FilmArray Respiratory Panel 2 plus (RP2plus) performance in a VTM sample matrix. Sample material is pooled and added to an equal volume of Viral Transport Medium (VTM) matrix. The VTM Protocol can be followed to test a total of 16 pooled samples, providing 4 positive results and 12 negative results per assay. The number of samples tested per day should be determined by the individual laboratory. The testing scheme can be modified to run more samples per day based on the number of instruments configured on the FilmArray System. VTM samples can be stored overnight (or up to 3 days) at refrigeration temperature (2 8 C) for subsequent testing to evaluate day-to-day variation. To evaluate userto-user variation, multiple laboratory technicians may perform testing. 6 P a g e FLM1-PRT-0240-01

Table 4. Proposed VTM Sample Preparation Scheme Pool 1 Organism Approximate organism volume Volume VTM Approximate Final Volume of Pool Adenovirus Type 3 Influenza A 2009 H1N1 Influenza B Parainfluenza virus Type 4 Coronavirus OC43 Pool 2 Rhinovirus 1 A Influenza A subtype H3 Coronavirus 229E Parainfluenza virus Type 1 Parainfluenza virus Type 2 Middle East Respiratory Coronavirus (MERS-CoV) Pool 3 Adenovirus Type 1 Influenza A H1N1 Parainfluenza virus Type 3 Respiratory Syncytial Virus A Coronavirus NL63 Bordetella parapertussis Pool 4 Adenovirus Type 31 Bordetella pertussis Chlamydia pneumoniae Mycoplasma pneumoniae Coronavirus HKU1 Human Metapneumovirus 8 1.5 ml 3.0 ml 1.8 ml 3.6 ml 1.8 ml 3.6 ml 1.8 ml 3.6 ml An example VTM Protocol workflow is provided below. VTM Protocol Example The estimated total time to completion for this VTM Protocol verification example is 4 days for a FilmArray 2.0 or Torch System configured with 1 module. Refer to Figure 2 for the suggested workflow. 7 P a g e FLM1-PRT-0240-01

Day 1 1. Prepare two sample pools (i.e. pools #1 and #2, in Table 4 above) from ZeptoMetrix NATRVP2-BIO and NATCOV(MR)-BIO control material and VTM. Note: It is important to prepare only the number of samples that will be tested within 3 days of preparation. The suggestion to prepare 2 sample pools is based on testing 4 pouches per day. The number of samples prepared may be increased or decreased based on the laboratory s work schedule and number of modules configured on the FilmArray System. a. Pipet 1.5 ml or 1.8 ml of VTM (as described in Table 4) into a sterile tube or vial. b. Use a transfer pipette to remove material from the ZeptoMetrix organism vial (draw material to the third line of the transfer pipette) and transfer to the tube containing VTM. c. Repeat with the second (and subsequent) organisms to combine the appropriate organisms into a single vial or tube (approximately 3.0 ml total volume for five organisms or 3.6 ml for six organisms). d. Cap and vortex prior to testing. 2. Test two samples (pouches) from a single VTM sample pool. The duplicate samples should be tested in a single day by different users. Note: For each sample, follow instructions in the FilmArray Respiratory Panel 2 plus Instruction Booklet and FilmArray Respiratory Panel 2 plus Quick Guide for pouch preparation, pouch hydration, sample loading, and sample testing. 3. Repeat Step 2 for the second sample pool (Pool #2 from Table 3) to be tested that day. 4. Refrigerate samples (2 8 C) for up to 3 days for the evaluation of day-to-day variation. Day 2 To examine day-to-day variation, test the samples prepared on Day 1 by repeating Step 2 and 3 above. Day 3 Prepare 2 new sample pools (i.e. pools #3 and #4) as described in Step 1. Test samples according to Step 2 and 3 above. Day 4 To evaluate day-to-day variation, test the samples prepared on Day 3 by repeating Step 2 and 3 above. Note: The remaining material from Zeptometrix NATRVP2-BIO may be stored according to manufacturer s instructions for use at a later date. 8 P a g e FLM1-PRT-0240-01

Figure 2. Workflow for VTM Protocol Example Verification of loaner and repaired instruments If it becomes necessary to verify the performance of a loaner or repaired instrument, the following protocol may serve as a guideline. 1. Select a few specimens and/or proficiency samples (any combination of positives and negatives) previously tested on the FilmArray Respiratory Panel 2 plus (RP2plus). The Laboratory Director should determine the appropriate number of samples to test. Two to six samples may be sufficient. Proficiency samples should not be pooled or diluted. 2. Test the selected specimens/samples on the loaner or repaired instrument and document the results. 9 P a g e FLM1-PRT-0240-01

Technical Support Contact Information BioFire is dedicated to providing the best customer support available. If you have any questions or concerns about this process, please contact the FilmArray Technical Support team for assistance. BioFire Technical Support Email: support@biofiredx.com Phone: +1-801-736-6354, select Option 5 10 P a g e FLM1-PRT-0240-01

FilmArray Respiratory Panel 2 plus Verification Record Computer System Serial Number #: FilmArray Respiratory Panel Kit Part #: Lot #: Organism/Sample Source and Lot #: Organism Detection Representative strains System Serial # Was the Organism Detected? Positive Negative Days Tested Users Patient Samples Tested? Type 1 C Adenovirus Type 3 B Type 31 A Bordetella parapertussis Bordetella pertussis Chlamydia pneumoniae Coronavirus 229E Coronavirus NL63 Coronavirus OC43 Coronavirus HKU1 Human Metapneumovirus Human Rhinovirus/Enterovirus Influenza A subtype H1 Influenza A subtype H1-2009 11 P a g e FLM1-PRT-0240-01

Organism Detection Representative strains System Serial # Was the Organism Detected? Positive Negative Days Tested Users Patient Samples Tested? Influenza A subtype H3 Influenza B Middle East Respiratory Coronavirus (MERS-CoV) Mycoplasma pneumoniae Parainfluenza virus 1 Parainfluenza virus 2 Parainfluenza virus 3 Parainfluenza virus 4 Respiratory Syncytial Virus Reviewed by: Signature Date 12 P a g e FLM1-PRT-0240-01